GLUCAGON-like peptide-1 agonistsTYPE 2 diabetesBLOOD sugarHYPOGLYCEMIC agentsGlucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing...
Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet β cells, promotion of islet β cell proliferation and ...
Introduction: Glucagon-like peptide 1 receptor agonists (GLP1-RA) are antihyperglycemic agents initially approved for the treatment of type 2 diabetes mellitus (T2DM). More recently, they are also used to achieve weight loss in patients with obesity. There are robust data that demonstrate consistent...
Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with increased risks for gallbladder or biliary diseases, with a higher risk for GLP-1 RA use in weight loss, according to a review published online March 28 in JAMA Internal Medi
like peptide-1 and glucosedependent insulinotropic polypeptide (GIP), which are both inactivated by dipeptidyl peptidase-4 (DPP-4). Those with type 2 diabetes may have a slowdown or stoppage of this process. However, using pharmaceutical doses of GLP-1 can restore insulin excretion. Delaying ...
Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with increased risks for gallbladder or biliary diseases, with a higher risk for GLP-1 RA use in weight loss, according to a review published online March 28 inJAMA Internal Medicine. ...
21.Ayoub M, Faris C, Juranovic T, Chela H, Daglilar E. The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.Cancers (Basel). 2024;16.[PubMed][DOI][Cited in This ...
glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of antidiabetic drugs noted not only for their potent glucose-lowering effects but also for their cardiovascular and renal protective benefits. Various GLP-1RAs have been demonstrated to have significant benefits in in vitro and in...
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have a beneficial weight-lowering effect in type 2 diabetes associated with a reduction incardiovascular mortality.116In the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial, ...
25.Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials.Metabolites. 2021;11.[PubMed][DOI][Ci...